Challenges In Biosimilar Monoclonal Antibody Cell Culture Process Development — Media Optimization Is A Key To Success
Source: TEVA Biopharmaceuticals
Biosimilar, a term synonymous to "follow-on biologic" requires very stringent and high standards of comparability with the original biologic drug that is being replicated. Unlike conventional small molecules and chemical generics, "biogenerics" or biosimilars, especially monoclonal antibodies, have complex structure and function that are affected by slight changes in the manufacturing process. Additionally, the rigor and stringent control standards imposed for biosimilars further increase the challenge and complexity for manufacturing process development of biosimilars.
access the Poster!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
This website uses cookies to ensure you get the best experience on our website. Learn more